ARTICLE SUMMARY:
After several years of waiting for the public market to re-open, medtech IPOs continue to remain healthy, while M&A deal numbers turn flat and valuations drop.
The long-awaited resurgence in medtech IPOs remained strong through the end of this year’s third quarter, with the total valuation of $475 million being the highest since 2015, while the number of deals remained roughly equivalent to the same period in both of the previous two years ( see Figure 1.)
